Small Molecule Targeted Protein Degradation Therapies 
Drug Discovery World
JULY 19, 2024
Biotechnology company Draupnir Bio has received equity investments totalling €12 million to support the company’s work in the field of targeted protein degradation (TPD).
Drug Discovery World
JANUARY 15, 2024
The collaboration leverages Evotec’s R&D platform to advance drug discovery for two drug targets that address major unmet medical needs of patients with Crohn’s disease and ulcerative colitis. billion in contingent milestone payments for three target programmes. of Perspective’s shares for up to $33 million.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
MARCH 22, 2023
It will combine the use of novel Huntington’s disease drug targets from Aitia’s Gemini Digital Twins with UCB’s expertise in drug research and preclinical model systems in neurodegeneration, with the aim to accelerate the discovery of new therapies for people living with Huntington’s disease.
Drug Discovery World
APRIL 6, 2023
from Fabien Vincent, Pfizer, Groton, US High content phenotypic and pathway profiling identifies novel drug mechanisms-of-action tailored towards cancers of unmet need by Neil Carragher, University of Edinburgh, Edinburgh, UK Functional genomics as an enabling tool for phenotypic screening by Matthew Garnett Chemistry to the Clinic: Part 1-3: (..)
Drug Discovery World
MAY 11, 2023
However, she also presented thoughts in a technical update, Targeted Protein Degradation – Progress, Direction and Prospects. Ubiquigent’s Sheelagh Frame, said: “It was wonderful to share experiences and thoughts about building better workplaces alongside some other inspiring women in life science.”
The Pharma Data
OCTOBER 15, 2020
a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE platform of targeted protein degradation technology, today announced that the company’s internal program to develop selective degraders that target key proteins within the TRK family has been published by the Journal of Medicinal Chemistry.
Drug Discovery World
OCTOBER 16, 2023
A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. CellProthera also appointed the Newcastle Centre for Life’s GMP cell therapy centre to produce the ATMP.”
Expert insights. Personalized for you.
130 
Let's personalize your content